Editorial: Tuberculosis Drug Discovery & Development: Drug Targets, Chemical Matter, and Approaches

Résumé

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the leading cause of death from a single infectious agent ranking it above all other contagious diseases.About one-third of the world's population is carrying Mtb and are at high risk of developing active TB, signifying the severity and widespread of this disease.The problem to tackle this disease appears to become even worse due to the recent outbreak of SARS-CoV-2.Further, the global number of TB cases are continuously rising which are fueled by poverty, HIV/AIDS, the emergence of multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of Mtb.Additionally, the drug-drug interaction issue with antiretrovirals and antidiabetics is a growing concern.The expanding threat of drug resistance has prompted urgent calls for new approaches to TB control, including the implementation of new modes of drug-susceptibility testing, use of alternative (shorter) therapeutic regimens aimed at expediting diagnosis and treatment, and most importantly to discover compounds (and regimens) with novel mechanisms of action (MoAs) (Singh and Chibale, 2021).The Research Topic aimed to address the current knowledge, research trends, and the future directions of TB drug discovery and development.The TB drug discovery and development mainly include two approaches for hit identification, the target-based -screening against a particular essential enzyme, and the phenotypic involving screening against wild-type or recombinant whole-Mtb cells.In contrast to other infectious disease drug discoveries, in TB, the whole-cell screening followed by elucidation of MoA has been the most successful approach in progressing novel drug-like compounds into the TB drug discovery pipeline (https://www.newtbdrugs.org/pipeline/discovery).Nonetheless, the novel target-based approaches based on new drug targets are coming up and have shown promise (Huszaŕ et al., 2020).In line with this, Oh et al. critically discussed various scaffolds that have been identified in the last 10 years from screens of small molecule libraries against whole-cells or targets where MoA investigation has defined target-hit couples and structure-activity relationship (SAR) studies have described the pharmacophore.The learnings shared by the authors are spot-on, viz.importance of various screening conditions mimicking the host environment; pairing structure-based with whole-cell read-outs was repetitive in yielding discrepancies -often perhaps due to the metabolism of scaffolds by Mtb cells; lipophilicity played an important role in whole-cell activity within a scaffold; failure of a series to progress was mainly due to the lack of in vivo efficacy in murine models of TB.In the case

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0